Published Online: Monday, March 1, 2004

Eisai Inc (Teaneck, NJ) recently announced that it has assumed US distribution responsibilities for Aciphex (rabeprazole sodium) from Janssen Pharmaceutica Inc affiliate JOM Pharmaceutical Services. Eisai and Janssen will continue to co-promote Aciphex, a proton pump inhibitor prescribed for gastro-esophageal reflux disease (GERD). Eisai is fulfilling purchase orders for Aciphex from a contract distribution center in Memphis, Tenn.The product is indicated for the treatment of symptomatic GERD, healing of erosive GERD, and maintenance of healed erosive GERD. Aciphex also is approved as part of the first 7-day treatment for Helicobacter pylori infections, the single most common cause of peptic ulcers. For more information, visit, or call 888-4ACIPHEX (888-422-4743).

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues